Concentration of polychlorinated biphenyls in serum from New Jersey biomonitoring study: 2016–2018

The first statewide New Jersey Biomonitoring (NJBM) of serum polychlorinated biphenyls (PCBs) was conducted from 2016 to 2018. Forty ortho-substituted PCBs were measured in serum samples collected from 920 NJ residents in compliance with the CDC method. The lipid adjusted geometric mean (GM) of ∑40PCB concentration for all the 920 measured subjects was 65.5 ng/g lipid (95% CIs: 56.9–75.4 ng/g lipid). Age stratified serum concentration showed that the lowest GM (33.3 ng/g lipid) was observed in the 20–39 years age group (n = 282), followed by a concentration of 76.05 ng/g lipid (n = 382) in the 40–59 years age group, and the highest GM (168.4 ng/g lipid) was found in the 60–74 years age group (n = 256). A survey regression model revealed that ∑40PCBs was significantly associated with age, moderately associated with geographic region, and not significantly associated with sex. The comparison of serum PCB levels in NJBM with the sequential National Health and Nutrition Examination Survey (NHANES) data suggested that the serum PCBs in NJ adults declined 52–59% at all age groups over the last decade. Positive Matrix Factorization (PMF) suggests that ongoing and recent exposure to lower molecular weight PCBs contributes about 15% to total serum PCB levels and more in younger subjects, while higher molecular weight PCBs contribute 52% of the total serum PCB levels and more in older subjects. •First baseline serum PCBs level study from New Jersey Biomonitoring (NJBM).•Serum PCB levels in older subjects continue declining trend suggested from NHANES.•Positive Matrix Factorization (PMF) resolved three distinct PCB profiles.